Oryzon Genomics SA Net Asset Quality Index
Oryzon Genomics SA net asset quality index. Oryzon Genomics SA (ORY) has a Net Asset Quality Index of 81.5% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €144.52 Million minus total liabilities of €26.68 Million yields net assets of €117.85 Million. A higher index indicates a stronger, lower-leverage balance sheet. See ORY net asset value for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Oryzon Genomics SA (2011–2025)
Net asset quality index of Oryzon Genomics SA from 2011 to 2025. This chart shows how Oryzon Genomics SA's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of December 2025, the index stands at 81.5%, representing net assets of €117.85 Million against total assets of €144.52 Million EUR. Check how strategically is Oryzon Genomics SA's equity deployed to assess the company's strategic physical and investment asset allocation.
Oryzon Genomics SA Net Asset Quality Index by Year (2011–2025)
Oryzon Genomics SA net asset quality index by year from 2011 to 2025. The table below presents the year-by-year Net Asset Quality Index for Oryzon Genomics SA from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Oryzon Genomics SA (ORY) market capitalisation.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 81.5% | €117.85 Million | €144.52 Million | €26.68 Million | ▲ +1.5 pp |
| 2024 | 80.1% | €87.04 Million | €108.72 Million | €21.67 Million | ▲ +3.6 pp |
| 2023 | 76.5% | €81.77 Million | €106.90 Million | €25.13 Million | ▲ +6.5 pp |
| 2022 | 70.0% | €72.57 Million | €103.70 Million | €31.13 Million | ▼ -4.7 pp |
| 2021 | 74.7% | €71.26 Million | €95.38 Million | €24.12 Million | ▼ -6.0 pp |
| 2020 | 80.7% | €75.93 Million | €94.11 Million | €18.18 Million | ▼ -19.2 pp |
| 2019 | 99.9% | €80.02 Million | €80.09 Million | €79.38K | ▲ +33.0 pp |
| 2018 | 66.9% | €45.13 Million | €67.45 Million | €22.33 Million | ▲ +10.5 pp |
| 2017 | 56.4% | €34.43 Million | €61.04 Million | €26.61 Million | ▲ +10.7 pp |
| 2016 | 45.7% | €22.73 Million | €49.74 Million | €27.02 Million | ▼ -22.1 pp |
| 2015 | 67.7% | €27.59 Million | €40.73 Million | €13.14 Million | ▲ +14.4 pp |
| 2014 | 53.3% | €13.89 Million | €26.06 Million | €12.16 Million | ▲ +2.1 pp |
| 2013 | 51.2% | €14.73 Million | €28.76 Million | €14.04 Million | ▼ -5.9 pp |
| 2012 | 57.1% | €16.43 Million | €28.78 Million | €12.35 Million | ▼ -0.3 pp |
| 2011 | 57.4% | €16.76 Million | €29.21 Million | €12.45 Million | — |